An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease
Affiliated Hospital of Jiangnan University
30 participants
May 31, 2024
INTERVENTIONAL
Conditions
Summary
The main pathological mechanism of Alzheimer's Disease (AD) is the abnormal deposition of amyloid-beta (Aβ) and tau proteins in the brain. Recent studies indicate that these two proteins are primarily cleared through the glymphatic system-meningeal lymphatic vessels-deep cervical lymphatic vessels pathway. Lymphatic circulation disorders in elderly patients can directly lead to the abnormal deposition of these proteins. Deep cervical lymphovenous bypass can improve lymphatic circulation and effectively treat lymphedema. This project aims to verify the effectiveness of 'deep cervical lymphovenous bypass' in treating AD, offering a new surgical treatment method to improve cognitive impairment and the quality of life for AD patients.
Eligibility
Inclusion Criteria5
- The age ranged from 60 to 80 years, and the time from initial diagnosis to enrollment was more than 12 months
- The estimated survival time is more than 12 months;
- The clinically diagnosed patients with mild to severe Alzheimer's Disease;
- The imaging examination has the correlation diagnosis evidence;
- Volunteer to participate in the project and sign an informed consent form with the guardian.
Exclusion Criteria6
- Complicated with other severe systemic underlying diseases;
- Unable to tolerate general anesthesia;
- The pregnant women;
- Recent severe infection or infectious diseases within 4 weeks;
- Unable to complete the evaluator or refused to complete the one-year clinical follow-up.
- Refusal to participate
Interventions
Deep cervical lymph-vein bypass surgery, connecting deep cervical lymph input vein vessel
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06448975